Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
August 8, 2014
- JPWA Members Still on Recovery Track with 0.88% Operating Margin in FY2013
August 8, 2014
- Half of Member Companies Report Price Settlements: Qol-Led Open Tender
August 8, 2014
- Linical Aims to Become “One-Stop” CRO for Global Clinical Trials
August 8, 2014
- Daiichi Sankyo Collaborates with US Venture for Analgesic in the US
August 8, 2014
- Daiwa Corporate Investment Establishes Venture Capital Firm Specializing in Biopharmaceuticals; Sights Set on Seeds of University Origin
August 7, 2014
- Development of Material for Treating Cartilage Injury Selected by NexTEP: Mochida
August 7, 2014
- Kyowa Kirin’s UK Subsidiary Completes Acquisition of Archimedes Pharma
August 7, 2014
- Santen Includes FY2017 Sales Target of 205 Billion Yen and Globalization in New Business Plan
August 6, 2014
- ASKA to Launch Blopress AGs on Sept 12
August 6, 2014
- Hisamitsu to Dissolve US JV with Novartis Pharmaceuticals
August 6, 2014
- Eli Lilly Japan Files NDA for GLP-1 Receptor Agonist Dulaglutide
August 6, 2014
- Eisai Ends Development of Diabetic Complication Treatment
August 5, 2014
- Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
- Otsuka, UCB Japan File E Keppra Injectable for Monotherapy
August 5, 2014
- Celgene Files NDA for Hematopoietic Malignancy Treatment Pomalidomide in Japan
August 5, 2014
- Kyowa Kirin Files NDA for Antithrombin Preparation KW-3357
August 5, 2014
- Asahi Kasei Pharma Files NDA for Xiaflex for Treatment of Dupuytren’s Contracture
August 4, 2014
- Taiho to Terminate Multinational PIII Study of Angiogenesis Inhibitor Orantinib for Hepatocellular Carcinoma
August 4, 2014
- Daiichi Sankyo to Transfer Akita Plant to Alfresa Pharma
August 4, 2014
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…